L3Harris Technology Supports Successful Launch of NASA’s Roman Space Telescope

L3Harris Technologies (NYSE: LHX) announced that key technology developed by the company is aboard NASA’s successfully launched Nancy Grace Roman Space Telescope, marking the culmination of more than a decade of collaboration with NASA.

L3Harris supplied Roman’s 2.4-meter Optical Telescope Assembly, which serves as the observatory’s primary optical system. The company also provided radiation-hardened electronics designed to keep the telescope operating approximately 1 million miles from Earth.

Once operational, Roman is expected to survey the cosmos around 1,000 times faster than the Hubble Space Telescope. Its missions include mapping billions of galaxies, observing hundreds of millions of stars and potentially identifying more than 100,000 distant worlds.

The telescope will also scan roughly 12% of the sky in less than 18 months, helping scientists study the expansion of the universe and observe supernova explosions dating back as far as 8 billion years.

The successful launch reinforces L3Harris’ position in the space and defense technology sector, particularly in advanced optics and mission-critical space systems. The company has previously contributed technology to major programs including the James Webb Space Telescope, Mars Perseverance and Curiosity rovers, GPS satellites and the International Space Station.

Aon to Acquire USI for $17 Billion, Expanding U.S. Middle-Market Insurance Business

Aon (NYSE: AON) announced Monday that it has agreed to acquire insurance brokerage firm USI from KKR and other shareholders for $17 billion, significantly expanding its presence in the U.S. middle-market insurance sector.

USI is the tenth-largest U.S. insurance broker, generating approximately $3 billion in annual revenue with more than 10,500 employees across nearly 200 offices. The company provides property and casualty insurance, employee benefits, personal risk and retirement solutions.

The acquisition builds on Aon's $13.4 billion purchase of NFP in 2024 and will substantially increase its exposure to the more than $40 billion U.S. middle-market segment. Aon will also gain greater access to the fast-growing Excess & Surplus insurance market, which accounts for about 26% of U.S. commercial property and casualty premiums.

Aon expects approximately $395 million in annual run-rate adjusted EBITDA benefits from revenue and cost synergies across its combined middle-market platform. The transaction is expected to become accretive to adjusted EPS beginning in 2028.

The $17 billion purchase will primarily be financed with new debt. As Aon prioritizes deleveraging following the transaction, the company said it does not expect to repurchase shares in the near term.

Following completion, USI Chairman and CEO Mike Sicard will become President of Aon and global CEO of its Middle Market business. The transaction is expected to close in the fourth quarter of 2026, subject to regulatory approvals.

The deal represents a major expansion of Aon's U.S. insurance brokerage operations, combining USI, NFP and Aon's existing businesses into a much larger middle-market platform while expanding its data and AI-enabled insurance capabilities.

U.S. Bank Expands Business Banking Operations Across High-Growth U.S. Markets

U.S. Bank (NYSE: USB) announced Monday that it is expanding its business banking operations into Florida and Georgia while accelerating its presence in Texas and Arizona as part of a broader national growth strategy.

The expansion marks the first time U.S. Bank has placed dedicated business bankers in Florida and Georgia, extending its reach beyond its traditional 26-state branch footprint. The bank is also adding bankers in Dallas following its expansion into Houston last year and growing its team in Phoenix.

U.S. Bank has added more than 50 client-facing positions to its business banking division since the beginning of 2026, with additional hiring planned. The division now includes more than 1,300 bankers serving businesses with annual sales between $2.5 million and $50 million.

The bank is targeting rapidly growing metropolitan markets while expanding services including deposits, lending, payments, treasury management and Small Business Administration loans. It is also continuing to build its healthcare banking business serving medical, dental and veterinary practices nationwide.

The expansion highlights U.S. Bank’s strategy of pursuing business banking growth beyond its physical branch network. It follows similar moves into Charlotte, Chicago, Houston and Las Vegas in 2025, giving the bank greater exposure to business customers in some of the fastest-growing U.S. markets.

SLB to Acquire Data Center Cooling Specialist Kelvion for $4.1 Billion

SLB (NYSE: SLB) has agreed to acquire Kelvion from Apollo-managed funds and Triton in a transaction valued at approximately $4.1 billion, significantly expanding its exposure to the rapidly growing AI data center infrastructure market.

Under the agreement, SLB will pay approximately $3.4 billion in cash and assume around $700 million of Kelvion debt. Apollo funds currently own a majority stake in Kelvion, while Triton holds a minority interest.

Kelvion develops advanced thermal management and cooling systems for data centers and industrial customers. Data centers have become the company's largest and fastest-growing segment as rising AI computing requirements drive demand for increasingly sophisticated cooling infrastructure.

The acquisition will complement SLB's existing data center solutions business, which has expanded rapidly over the past three years and expects cumulative deliveries to exceed 2 gigawatts globally by year-end.

SLB said adding Kelvion will more than double its potential revenue opportunity for each gigawatt of data center capacity delivered. The deal therefore represents a significant expansion beyond SLB's traditional energy technology operations and positions the company to capture more spending from the global AI infrastructure buildout.

The transaction is expected to close in the first half of 2027, subject to regulatory approvals and other customary closing conditions.

CrowdStrike Brings Falcon Cybersecurity Platform to Google Cloud

CrowdStrike (NASDAQ: CRWD) announced Monday that its Falcon cybersecurity platform is now available on Google Cloud infrastructure, expanding deployment options for enterprises operating across multiple cloud environments.

The integration allows customers to run Falcon on U.S.-based Google Cloud infrastructure while maintaining CrowdStrike’s unified security capabilities across AI agents, endpoints, identities, cloud environments and data.

A key focus of the partnership is data sovereignty. Enterprises can keep sensitive security data within selected Google Cloud regions, helping meet localization and regulatory requirements while reducing the complexity associated with managing separate cybersecurity systems across different cloud providers.

CrowdStrike plans to expand Falcon availability to additional Google Cloud regions following the initial U.S. deployment.

The agreement is particularly relevant as enterprises increasingly operate multi-cloud environments and deploy AI workloads containing sensitive corporate data. CrowdStrike is positioning Falcon as a single security layer capable of protecting these environments regardless of the underlying cloud provider.

For CrowdStrike, the Google Cloud deployment expands the reach of its AI-native Falcon platform and supports its broader strategy of consolidating multiple cybersecurity functions onto a single platform. For Google Cloud, the partnership strengthens its enterprise security ecosystem as competition for AI and cloud workloads intensifies.

Abbott Reports Positive Phase 3-Style Clinical Data for TactiFlex Duo AFib Catheter

Abbott (NYSE: ABT) announced positive 12-month clinical results for its investigational TactiFlex Duo Ablation Catheter, a device designed to treat challenging cases of atrial fibrillation (AFib).

TactiFlex Duo combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single catheter, allowing physicians to select or combine ablation approaches depending on a patient’s needs. The technology works with Abbott’s EnSite X cardiac mapping system to provide real-time feedback during procedures.

In the FlexPulse Global IDE study, 92.6% of patients with paroxysmal AFib had no documented recurrence of AFib, atrial flutter or atrial tachycardia under standard-of-care monitoring. Under more rigorous protocol-driven monitoring, 77.4% remained free from documented recurrence.

The study also met its primary effectiveness endpoint, with 74.6% of patients remaining free from documented arrhythmias, medication changes or repeat procedures. Abbott reported a 98.3% safety rate with no major safety events.

The results are important for Abbott’s electrophysiology business as competition intensifies in the fast-growing PFA market. Combining PFA and traditional RF energy in one catheter could differentiate TactiFlex Duo by giving physicians greater flexibility when treating more complex arrhythmias.

The device received CE Mark in Europe earlier this year, while the FlexPulse IDE study is intended to support an application for U.S. FDA approval. The latest data were presented at the European Society of Cardiology Congress 2026 and published in EP Europace.

Amgen’s Repatha Cuts Risk of Death by 20% in High-Risk Patients

Amgen (NASDAQ: AMGN) announced Monday that its cholesterol-lowering drug Repatha reduced the risk of death by 20% among high-risk adults who had not previously suffered a heart attack or stroke, according to a pre-specified analysis of the Phase 3 VESALIUS-CV trial.

The study included more than 12,000 patients and evaluated Repatha alongside statins or other LDL cholesterol-lowering treatments. Amgen said the drug produced meaningful reductions in both all-cause and cardiovascular mortality, with the mortality benefit beginning to emerge after approximately 1.5 years and continuing through a median follow-up of 4.6 years.

The findings make Repatha the first PCSK9 inhibitor to demonstrate a reduction in all-cause mortality in a Phase 3 trial involving high-risk primary-prevention patients, according to Amgen. The results were presented at the European Society of Cardiology Congress 2026 and simultaneously published in Circulation.

Additional analyses strengthened the cardiovascular case for Repatha. The treatment reduced first, subsequent and total cardiovascular events, while a reduction in heart-attack risk was observed as early as six months after treatment began. The benefit was primarily associated with fewer heart attacks caused by atherosclerotic plaque rupture and fewer larger infarctions.

The results could strengthen Repatha’s position in the cardiovascular market by supporting earlier and more aggressive LDL reduction before patients experience their first major cardiovascular event. Amgen also presented real-world studies showing that many high-risk patients remain undertreated and fail to reach recommended LDL cholesterol targets, suggesting a potentially significant population that could benefit from more intensive lipid-lowering therapy.

Adobe Expands Saudi AI Partnership With Over $4 Billion in Free Creative Tools

Adobe (NASDAQ: ADBE) announced Monday an expanded partnership with Saudi Arabia’s Ministry of Communications and Information Technology (MCIT) and HUMAIN, providing millions of people across the Kingdom with access to its AI-powered creative tools.

Under the initiative, Adobe plans to give more than 27 million eligible Saudi citizens and residents aged 13 and older 12 months of free access to Adobe Firefly Standard and Adobe Express Premium features. Adobe values the commitment at more than $4 billion.

The partnership also includes a new AI image-generation model jointly developed by Adobe and HUMAIN using Adobe Firefly Foundry. The model will be tuned to Saudi culture and designed to generate culturally relevant imagery using Arabic-language prompts.

Adobe is also expanding Arabic support across its products. Adobe Express now offers Modern Standard Arabic right-to-left support across desktop, web and iOS, including typography, text editing and culturally tailored templates.

The initiative extends beyond consumers. Beginning in early 2027, eligible Saudi startups participating in MCIT-backed entrepreneurship programs will receive free access to selected Adobe tools, training and expertise. Adobe and MCIT also plan to provide AI and creative-skills training through Adobe Digital Academy.

The expanded agreement strengthens Adobe’s position in the growing generative AI market while giving the company large-scale exposure to Saudi Arabia’s rapidly developing AI and digital economy. It also deepens Adobe’s relationship with HUMAIN as Saudi Arabia invests heavily in AI infrastructure, locally relevant models and technology skills.

Eli Lilly Reports Strong One-Year Results for Taltz and Zepbound Combination

Eli Lilly (NYSE: LLY) announced positive 52-week Phase 3b data Monday showing that Taltz and Zepbound used together produced durable improvements in adults with psoriatic disease and obesity.

The results come from the TOGETHER-PsO and TOGETHER-PsA trials, which compared Taltz plus Zepbound with Taltz alone. The combination had already demonstrated statistically superior results at the Week 36 primary endpoint, and Lilly said those improvements were maintained or further strengthened through Week 52.

In the psoriasis trial, 30.6% of patients receiving the combination achieved both complete skin clearance and at least 10% weight loss, compared with 4.4% receiving Taltz alone. Complete skin clearance was achieved by 40.5% of combination-treated patients versus 29.1% with Taltz alone.

Results were also strong in psoriatic arthritis. About 39.2% of patients receiving both drugs achieved at least a 50% improvement in disease activity together with at least 10% weight loss, compared with just 1.7% in the Taltz-only group. The proportion achieving a 50% improvement in disease activity reached 43.7% versus 15.7% with monotherapy.

The combination also produced sustained or improved results across measures including systemic inflammation, BMI, blood pressure, glucose, HbA1c, triglycerides and cholesterol. No new safety concerns were identified, with adverse events generally mild to moderate and consistent with the known profiles of the two medicines.

The findings are significant for Lilly because they suggest Zepbound's role could extend beyond weight management when used alongside established therapies for diseases closely associated with obesity. The data could strengthen the company's position across both the rapidly growing obesity market and immunology, while supporting a broader strategy of treating interconnected metabolic and inflammatory diseases.

PPG Launches One Range Marine Coatings to Simplify Vessel Maintenance

PPG (NYSE: PPG) announced Monday the launch of its PPG One Range portfolio, a new line of one-component marine coatings designed to simplify onboard vessel maintenance and improve application efficiency.

Introduced at the SMM 2026 maritime trade fair in Hamburg, the portfolio consists of five ready-to-use coatings that eliminate mixing requirements. PPG said the products can reduce preparation time, simplify storage and handling, and minimize coating waste for ship crews performing routine maintenance.

The portfolio includes waterborne, alkyd and polyurethane technologies for interior and exterior applications. Certain technologies also support low volatile organic compound requirements and low flame-spread certification.

PPG is also previewing its PowerPack application tool, a portable battery-powered system designed for use with the One Range coatings. The system allows crews to switch between roller and brush applications using a single unit, potentially reducing equipment changes and improving productivity.

The launch expands PPG’s offering in the protective and marine coatings market, where reducing vessel downtime and maintenance costs can be important considerations for fleet operators. By combining simpler coatings with a dedicated application system, PPG is targeting more efficient onboard maintenance while strengthening its position in specialized industrial coatings.